Table 2.

Risk of outcomes^a between CKD versus CKD and HF patients in the prevalent population after 3 years of follow-up

Group	Endpoint	Follow-up (median, days)	Events, n	%	Event rates per 100 patient-years	HRb (CKD and HF versus CKD)	95% CI	P-value
CKD and HF	All-cause death	428	3132	37.3	17.1	1.107	1.064–1.153	<.001
CKD		506	10 701	22.9	10.1
CKD and HF	Heart failure	447	3994	47.6	21.7	1.439	1.387–1.493	<.001
CKD		541	8293	17.7	7.1
CKD and HF	CKD	545	2097	25.0	10.2	1.019	0.964–1.078	.505
CKD		408	4114	8.8	3.6
CKD and HF	UACR Progression: <30 to 30–300 mg/g	504	43	0.5	0.2	1.300	0.961–1.761	.089
CKD		551	1865	4.0	1.6
CKD and HF	UACR Progression: 30–300 to >300 mg/g	490	1158	13.8	5.5	1.323	1.182–1.481	<.001
CKD		558	451	1.0	0.4
CKD and HF	UACR Regression: ≥30 to <30 mg/g	522	85	1.0	0.4	1.147	0.854–1.538	.363
CKD		601	109	0.2	0.1
CKD and HF	UACR Regression: ≥300 to <300 mg/g	493	40	0.5	0.2	1.166	0.789–1.721	.441
CKD		552	80	0.2	0.1
CKD and HF	Acute kidney failure (ICD-10 code N17)	592	164	2.0	0.7	1.082	0.784–1.493	.633
CKD		532	686	1.5	0.6

^aAll-cause mortality and first hospitalization for cardiorenal events (HF, CKD, acute kidney failure) or albuminuria transitions during follow-up.

^bHR was adjusted according to age, sex, eGFR and the number of associated clinical conditions.